https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27836 Wed 27 Apr 2022 14:46:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14160 -/-), 4^-/- or 2/4^-/- BALB/c mice. Wt mice had moderate disease and infection. TLR2^-/- mice had more severe disease and more intense and prolonged infection compared to other groups. TLR4^-/- mice were asymptomatic. TLR2/4^-/- mice had severe early disease and persistent infection, which resolved thereafter consistent with the absence of symptoms in TLR4^-/- mice. Wt mice mounted robust innate and adaptive responses with an influx of natural killer (NK) cells, neutrophils, myeloid (mDCs) and plasmacytoid (pDCs) dendritic cells, and activated CD4⁺ and CD8⁺ T-cells into the lungs. Wt mice also had effective production of interferon (IFN)c in the lymph nodes and lung, and proliferation of lymph node T-cells. TLR2^-/- mice had more intense and persistent innate (particularly neutrophil) and adaptive cell responses and IL-17 expression in the lung, however IFNγ responses and T-cell proliferation were reduced. TLR2/4^-/- mice had reduced innate and adaptive responses. Most importantly, neutrophil phagocytosis was impaired in the absence of TLR2. Thus, TLR2 expression, particularly on neutrophils, is required for effective control of Chlamydia respiratory infection in early life. Loss of control of infection leads to enhanced but ineffective TLR4-mediated inflammatory responses that prolong disease symptoms. This indicates that TLR2 agonists may be beneficial in the treatment of early life Chlamydia infections and associated diseases.]]> Wed 11 Apr 2018 13:47:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48761 Wed 05 Apr 2023 13:49:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29881 n=249) or placebo spray (n=256); after six hours, they could re-dose every three–six hours as required, for three days (max. five doses/day). The primary endpoint was the area under the change from baseline curve in throat soreness from zero–two hours (AUC_0–2h). The change from baseline in other sore throat symptoms also assessed efficacy. Results: The mean AUC_0–2h for throat soreness was significantly greater with flurbiprofen spray (-1.82; 95% CI: -1.98 to 1.65) compared with placebo (-1.13; 95% CI: -1.27 to 0.99)(P<0.0001). Significantly greater reductions from baseline were observed with flurbiprofen spray compared with placebo from the first time-points assessed (five minutes for throat soreness/difficulty swallowing, 20 minutes for sore throat pain intensity and 30 minutes for swollen throat) for up to six hours (P<0.05 for all). There was no significant difference in adverse events between treatment groups during the three-day study. Conclusion: Flurbiprofen spray provides rapid and long-lasting relief from sore throat symptoms, and is well-tolerated over three days.]]> Thu 21 Sep 2017 14:45:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48080 Mon 03 Apr 2023 09:57:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27837 Fri 22 Apr 2022 10:33:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33265 Fri 21 Sep 2018 14:23:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53147 Fri 17 Nov 2023 11:28:55 AEDT ]]>